Detalhe da pesquisa
1.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Ann Rheum Dis
; 79(11): 1478-1484, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32759258
2.
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Invest New Drugs
; 38(5): 1472-1482, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172489
3.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Invest New Drugs
; 39(1): 285-286, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32578153
4.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Invest New Drugs
; 39(1): 283-284, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474843
5.
Single-crossover recombination and ancestral recombination trees.
J Math Biol
; 68(6): 1371-402, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23564407
6.
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
PLoS One
; 18(10): e0292307, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37847688
7.
Single-crossover recombination in discrete time.
J Math Biol
; 60(5): 727-60, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19636557
8.
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet Respir Med
; 7(7): 569-580, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31103412
9.
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Eur J Drug Metab Pharmacokinet
; 43(5): 533-541, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500603
10.
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Lung Cancer
; 120: 27-33, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748012
11.
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Clin Lung Cancer
; 18(5): 589-593, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28690011
12.
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
J Clin Oncol
; 35(31): 3591-3600, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28892431
13.
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
Leukemia
; 33(10): 2531-2535, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31089249